These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29878685)

  • 21. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant rectal score: run with the hare and hunt with the hounds.
    Sclafani F; Kalaitzaki E; Cunningham D; Tait D; Brown G; Chau I
    Ann Oncol; 2018 Nov; 29(11):2261-2262. PubMed ID: 30204839
    [No Abstract]   [Full Text] [Related]  

  • 23. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?
    Yu SK; Tait D; Chau I; Brown G
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):505-11. PubMed ID: 24074924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Controversies and progress in adjuvant chemotherapy for patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy].
    Li XX; Li QG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):594-596. PubMed ID: 31238639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Endorectal Ultrasound, MRI, and Mucosa Integrity Accurately Predict the Complete Response for Mid-Low Rectal Cancer After Preoperative Chemoradiation? A Prospective Observational Study from a Single Medical Center.
    Liu S; Zhong GX; Zhou WX; Xue HD; Pan WD; Xu L; Lu JY; Wu B; Lin GL; Qiu HZ; Xiao Y
    Dis Colon Rectum; 2018 Aug; 61(8):903-910. PubMed ID: 29944579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer.
    Choi MH; Oh SN; Rha SE; Choi JI; Lee SH; Jang HS; Kim JG; Grimm R; Son Y
    J Magn Reson Imaging; 2016 Jul; 44(1):212-20. PubMed ID: 26666560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging trends in the treatment of rectal cancer.
    Minsky BD
    Acta Oncol; 2019 Oct; 58(10):1343-1351. PubMed ID: 31271081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
    Cho H; Kim JE; Kim KP; Yu CS; Kim JC; Kim JH; Lee MA; Jang HS; Oh ST; Kim SY; Oh JH; Kim DY; Hong YS; Kim TW
    Am J Clin Oncol; 2016 Dec; 39(6):623-629. PubMed ID: 27322695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rectal Cancer: Assessing Response to Neoadjuvant Therapy.
    Maas M; Dijkhoff RAP; Beets-Tan R
    Magn Reson Imaging Clin N Am; 2020 Feb; 28(1):117-126. PubMed ID: 31753231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery.
    Tomasello G; Ghidini M; Petrelli F
    Eur J Cancer; 2019 Feb; 108():97-99. PubMed ID: 30648634
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular markers for recurrence and sensitivity to preoperative chemoradiotherapy in locally advanced rectal tumours.
    Romain B; Meyer N; Brigand C; Chenard MP; Schneider A; Guenot D
    Dig Surg; 2014; 31(4-5):347-53. PubMed ID: 25503074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application value of biplane transrectal ultrasonography plus ultrasonic elastosonography and contrast-enhanced ultrasonography in preoperative T staging after neoadjuvant chemoradiotherapy for rectal cancer.
    Xiao Y; Xu D; Ju H; Yang C; Wang L; Wang J; Hazle JD; Wang D
    Eur J Radiol; 2018 Jul; 104():20-25. PubMed ID: 29857861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of neoadjuvant radiotherapy for rectal cancer : Is MRI-based selection a future model?].
    Kulu Y; Hackert T; Debus J; Weber MA; Büchler MW; Ulrich A
    Chirurg; 2016 Jul; 87(7):573-8. PubMed ID: 27339645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer.
    Sada YH; Tran Cao HS; Chang GJ; Artinyan A; Musher BL; Smaglo BG; Massarweh NN
    J Surg Res; 2018 Jun; 226():15-23. PubMed ID: 29661280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy.
    Bhoday J; Smith F; Siddiqui MR; Balyasnikova S; Swift RI; Perez R; Habr-Gama A; Brown G
    Dis Colon Rectum; 2016 Oct; 59(10):925-33. PubMed ID: 27602923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of volumetric apparent diffusion coefficient histogram analysis for assessing complete response and clinical outcomes following pre-operative chemoradiation treatment for rectal carcinoma.
    Chidambaram V; Brierley JD; Cummings B; Bhayana R; Menezes RJ; Kennedy ED; Kirsch R; Jhaveri KS
    Abdom Radiol (NY); 2017 May; 42(5):1310-1318. PubMed ID: 28004138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemoradiotherapy for rectal cancer: how important is tumour regression?
    McCoy MJ; Hemmings C; Hillery S; Penter C; Bulsara MK; Zeps N; Platell CF
    ANZ J Surg; 2017 Dec; 87(12):E233-E239. PubMed ID: 26631340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.